ArticleAmino acids2025
Rational designing and synthesizing an antimicrobial peptide from bovine milk casein and evaluating its biological properties.
Article in Amino acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The overuse of antibiotics has led to a growing crisis-antimicrobial resistance, making it harder to treat infections and pushing scientists to find new solutions. Among the most promising alternatives are bioactive peptides, especially antimicrobial peptides, which offer broad-spectrum activity with a lower risk of resistance. One exciting source of these peptides is milk, particularly casein-derived peptides, which naturally possess antimicrobial properties. This study focused on bovine milk casein to design and synthesize a novel antimicrobial peptide. We evaluated several properties, such as antimicrobial activity, cytotoxicity, stability, and structure, using computational predictions to select the most promising candidate. The peptide NCP1 emerged as the best option and was synthesized for lab testing. Our results showed that NCP1 has antifungal activity and effectively stops the growth of Candida albicans with a minimum fungicidal concentration (MFC) of 250 µg/mL in less than four hours. It also prevented biofilm formation, interacted with DNA, and bound to ergosterol, ultimately damaging the fungal cell wall. Additionally, NCP1 demonstrated feeble antibacterial effects, particularly against Staphylococcus aureus and Pseudomonas aeruginosa. However, its antibacterial impact weakened over time due to interactions with environmental salts. Since the NCP1 peptide has low cytotoxicity and kills the yeasts selectively, further refinements to improve its potency and stability could pave the way for our future study of the presentation of a potent antimicrobial peptide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.